menu
    • menu

    Company profile for CellCentric

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CellCentric is a clinical stage biotechnology company focused on the development of the novel drug CCS1477 for specific cancers. CellCentric is a UK based biotechnology company with offices in Cambridge, Oxford and Manchester (Alderley Park). It has partnered and collaborated with researchers and clinicians across the world, from West Coast USA to Japan. The company is privately held; it’s lead investor is Boston based, Morn...
    CellCentric is a clinical stage biotechnology company focused on the development of the novel drug CCS1477 for specific cancers. CellCentric is a UK based biotechnology company with offices in Cambridge, Oxford and Manchester (Alderley Park). It has partnered and collaborated with researchers and clinicians across the world, from West Coast USA to Japan. The company is privately held; it’s lead investor is Boston based, Morningside Ventures. The company’s leadership has deep R&D experience gained in academia, large pharma and biotechs, spanning from basic biological research through to international clinical development programmes.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CellCentricunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Chesterford Research Park Little Chesterford Cambridge CB10 1XL
    Telephone
    Telephone
    +44 1799 531130
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cellcentric.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer-backed CellCentric secures $120M for ph. 3 myeloma trial
    Pfizer-backed CellCentric secures $120M for ph. 3 myeloma trial

    20 May 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/pfizer-backed-cellcentric-secures-120m-further-myeloma-trials

    FIERCE BIOTECH
    20 May 2025
    Share Share
    British biotech CellCentric expands to Boston, plans hiring push
    British biotech CellCentric expands to Boston, plans hiring push

    02 Apr 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/british-biotech-cellcentric-expands-boston-plans-grow-late-stage-clinical-development

    FIERCE BIOTECH
    02 Apr 2025
    Share Share
    CellCentric to present inobrodib Phase I multiple myeloma efficacy data
    CellCentric to present inobrodib Phase I multiple myeloma efficacy data

    04 Nov 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/cellcentric-to-present-inobrodib-phase-i-multiple-myeloma-efficacy-and-safety-data-at-the-american-society-of-haematology-301668106.html

    PRNEWSWIRE
    04 Nov 2022
    Share Share
    CellCentric Strengthens Leadership Team
    CellCentric Strengthens Leadership Team

    06 Apr 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/cellcentric-strengthens-leadership-team-301518268.html

    PRNEWSWIRE
    06 Apr 2022
    Share Share
    CellCentric secures investment from ASC's venture capital fund for inobrodib
    CellCentric secures investment from ASC's venture capital fund for inobrodib

    26 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/cellcentric-secures-investment-from-american-cancer-societys-impact-venture-capital-fund-to-advance-inobrodib-its-ground-breaking-p300cbp-targeted-therapy-301467871.html

    PRNEWSWIRE
    26 Jan 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search